Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 703-709

  Alarma Estrany, Pilar ^a   Guzman Aranguez, Ana ^a   Huete, Fernando ^a   Peral, Assumpta ^a   Plourde Jr , Robert ^b   Pelaez, Teresa ^a   Yerxa, Benjamin ^b   Pintor, Jesús ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(5 METHOXY 1H INDOL 3 YL)METHYLPHOSPHORAMIDIC ACID DIPHENYL ESTER; 1 [(5 METHOXY 1H INDOL 3 YL)METHYL] 6 OXOPIPERIDINE 2 CARBOXYLIC ACID; 1 METHYLENE 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YLCARBAMIC ACID METHYL ESTER; 2 BROMO 3 (2 ETHANAMIDOETHYL) 1H INDOL 5 YLCARBAMIC ACID METHYL ESTER; 2 BROMO 3 (ETHANAMIDOMETHYL) 1H INDOL 5YLCARBAMIC ACID METHYL ESTER; 3 (2 ETHANAMIDOETHYL) 1 METHYL 1H INDOL 5 YL(METHYL)CARBAMIC ACID METHYL ESTER; 3 (ETHANAMIDOMETHYL) 1H INDOL 5 YLCARBAMIC ACID; 3 (ETHANAMIDOMETHYL) 1H INDOL 5 YLCARBAMIC ACID METHYL ESTER; 3 (ETHANAMIDOMETHYL) 2 METHYL 1H INDOL 5YLCARBAMIC ACID METHYL ESTER; 3 (PROPANAMIDOMETHYL) 1H INDOL 5YLCARBAMIC ACID METHYL ESTER; HORMONE RECEPTOR BLOCKING AGENT; INS 48476; INS 48497; INS 48793; INS 48803; INS 48834; INS 48836; INS 48838; INS 48848; INS 48852; INS 48853; INS 48862; INS 48863; INS 48864; INS 48879; INS 48882; INS 48887; LUZINDOLE; MELATONIN 2 RECEPTOR; MELATONIN 3 RECEPTOR; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; N [(5 METHOXY 1H INDOL 3 YL)METHYL] 2 METHYLPROPANAMIDE; N [(5 METHOXY 1H INDOL 3 YL)METHYL]BENZAMIDE; N [(5 METHOXY 1H INDOL 3 YL)METHYL]METHANESULFONAMIDE; N [(5 METHOXY 1H INDOL 3 YL)METHYL]PROPANAMIDE; N [2 (5 METHOXY 1H INDOL 3 YL)ETHYL] 3 PHENYLPROP 2 ENAMIDE; N PENTANOYL 2 BENZYLTRYPTAMINE; PRAZOSIN; S (BUTYLPEROXY) N [(5 METHOXY 1H INDOL 3 YL)METHYL]THIOHYDROXYLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; EYE; GLAUCOMA; INTRAOCULAR PRESSURE; ISOINDOLES; MELATONIN; OCULAR HYPERTENSION; RABBITS; RECEPTOR, MELATONIN, MT2; RECEPTORS, MELATONIN; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TRYPTAMINES;

EID: 79956213259     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.178319     Document Type: Article

References (24)

1. Alarma-Estrany P, Crooke A, Peral A, and Pintor J (2007) Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT. Auton Neurosci 137:63-66. (Pubitemid 350101431)
2. Alarma-Estrany P, Crooke A, Mediero A, Peláez T, and Pintor J (2008) Sympathetic nervous system modulates the ocular hypotensive action of MT2-melatonin receptors in normotensive rabbits. J Pineal Res 45:468-475.
3. Alarma-Estrany P, Crooke A, and Pintor J (2009) 5-MCA-NAT does not act through NQO2 to reduce intraocular pressure in New-Zealand white rabbit. J Pineal Res 47:201-209.
4. Andrés-Guerrero V, Alarma-Estrany P, Molina-Martínez IT, Peral A, Herrero- Vanrell R, and Pintor J (2009) Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT. Exp Eye Res 88:504-511.
5. Bito LZ (1984) Species differences in the responses of the eye to irritation and trauma: a hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research. Exp Eye Res 39:807-829.
6. Chen Y, Tjong YW, Ip SF, Tipoe GL, and Fung ML (2005) Melatonin enhances the hypoxic response of rat carotid body chemoreceptor. J Pineal Res 38:157-163. (Pubitemid 40396173)
7. Draize JH, Woodard G, and Calvery HO (1944) Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82:377-390.
8. Dubocovich ML (1995) Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 16:50-56.
9. Komaromy AM, Brooks DE, Kubilis PS, Dawson WW, Sapp HL Jr, Nelson G, Collins BR, and Sherwood MB (1998) Diurnal intraocular pressure curves in healthy rhesus macaques (Macaca mulatta) and rhesus macaques with normotensive and hypertensive primary open-angle glaucoma. J Glaucoma 7:128-131. (Pubitemid 28196101)
10. Lewy AJ (1999) Melatonin as a marker and phase-resetter of circadian rhythms in humans. Adv Exp Med Biol 460:425-434.
11. Macor JE, Post R, and Ryan K (1993) A simple synthesis of 5-amino-3-(2- dimethylaminoethyl) indole[5-amino-N,N-dimethyl-tryptamine]. Synthetic Communications 23:65-72. (Pubitemid 23038908)
12. Mendoza-Vargas L, Solís-Chagoyán H, Benítez-King G, and Fuentes-Pardo B (2009) MT2-like melatonin receptor modulates amplitude receptor potential in visual cells of crayfish during a 24-hour cycle. Comp Biochem Physiol A Mol Integr Physiol 154:486-492.
13. Moore RY (1997) Circadian rhythms: basic neurobiology and clinical applications. Annu Rev Med 48:253-266.
14. 125I]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther 290:334-340.
15. Pintor J, Martin L, Pelaez T, Hoyle CH, and Peral A (2001) Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol 416:251-254. (Pubitemid 32274253)
16. Pintor J, Peláez T, Hoyle CH, and Peral A (2003) Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br J Pharmacol 138:831-836. (Pubitemid 36390639)
17. Pointer JS (1997) The diurnal variation of intraocular pressure in non-glaucomatous subjects: relevance in a clinical context. Ophthalmic Physiol Opt 17:456-465.
18. Rohde BH, McLaughlin MA, and Chiou LY (1985) Existence and role of endogenous ocular melatonin. J Ocul Pharmacol 1:235-243. (Pubitemid 17187192)
19. Schottenstein EM (1996) Intraocular pressure and tonometry, in The Glaucomas, Basic Sciences (Ritch R, Shields MB, and Krupin T, eds), pp 407-408, CV Mosby, St. Louis, MO.
20. Serle JB, Wang RF, Peterson WM, Plourde R, and Yerxa BR (2004) Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma 13:385-388. (Pubitemid 39281579)
21. Sugden D, Yeh LK, and Teh MT (1999) Design of subtype selective melatonin receptor agonists and antagonists. Reprod Nutr Dev 39:335-344. (Pubitemid 30088361)
22. Thylefors B and Négrel AD (1994) The global impact of glaucoma. Bull WHO 72:323-326. (Pubitemid 24232504)
23. Xia CM, Shao CH, Xin L, Wang YR, Ding CN, Wang J, Shen LL, Li L, Cao YX, and Zhu DN (2008) Effects of melatonin on blood pressure in stress-induced hypertension in rats. Clin Exp Pharmacol Physiol 35:1258-1264.
24. Yoshida F and Topliss JG (1996) Unified model for the corneal permeability of related and diverse compounds with respect to their physicochemical properties. J Pharm Sci 85:819-823. (Pubitemid 26269475)